Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.

Straus, D J

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Nov 1998 - 3601-6 p. digital

Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.

0732-183X

10.1200/JCO.1998.16.11.3601 doi


Adolescent
Adult
Age Factors
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bleomycin--administration & dosage
CD4 Lymphocyte Count
Child
Cyclophosphamide--administration & dosage
Dexamethasone--administration & dosage
Doxorubicin--administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor--administration & dosage
Humans
Leucovorin--administration & dosage
Lymphoma, AIDS-Related--mortality
Methotrexate--administration & dosage
Middle Aged
Multivariate Analysis
Prognosis
Vincristine--administration & dosage